Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Validated Cost Effectiveness of Medtronic Reveal LINQ
Author(s): Klaus Witte , Matthew Reynolds , Paul Guyler Start date: Oct 13, 2020

Electrophysiology & Arrhythmia
ACC 23: The UK Mini Mitral Study
Author(s): Enoch Akowuah Added: 1 year ago
ACC.23/WCC—DrEnoch Akowuah (James Cook University Hospital, UK) joins us to share the findings of the UK Mini-Mitral trial (National Institute of Health Research). This study is a multicentre, expertise-based randomised controlled trial that aimed to compare the safety and effectiveness of a minimally-invasive thoracotomy compared to conventional sternotomy in treating patients with degenerative… View more

Vascular Disease and Surgery

Intervention
Author(s): Frederic Baumann , Nicolas Diehm Added: 3 years ago
Chronic critical limb ischaemia (CLI) affects a defined subgroup of patients with systemic atherosclerosis. Often, these patients exhibit additional cardiovascular risk factors and co-morbidities, which complicate their disease pattern and limit treatment modalities. Therefore, CLI is clearly associated with excessive morbidity and mortality rates and leads to a substantial decline in quality of… View more

Vascular Disease and Surgery

MI/ACS
Author(s): Covadonga Fernández-Golfín , Jose Luis Zamorano Added: 3 years ago
Since the introduction in the early 1980s of magnetic resonance imaging (MRI) in clinical practice, contrast agents (CAs) have been part of MR studies enhancing the capabilities of this diagnostic technique. CAs enhance the contrast between different types of tissues. Tissue contrast depends largely on proton concentration and longitudinal (T1) and transversal (T2) relaxation times inherent to… View more

Imaging & Diagnostics
Author(s): Christopher S Hayward , Marc Swartz Added: 3 years ago
Heart failure is an escalating global pandemic and one of the leading causes of death and disability in the developed world. At present, the incidence of heart failure in the Western world is staggering, affecting approximately 6.5 million people in Europe and 5.8 million people in the US.1–3 Even more alarming is the notion that approximately 10 % of this population suffers from advanced heart… View more

Imaging & Diagnostics

Heart Failure
ESC 22: 3 Trials That Will Change Your Practice With Dr Alasnag
Author(s): Mirvat Alasnag Added: 1 year ago
ESC Congress 22 —In this short and practice-focused review, Dr Mirvat Alasnag (The King Fahd Armed Forces Hospital, Jeddah, SA) shares her thoughts about 3 late ESC hot trials that will have an impact on her practice as an interventionalist cardiologist. Trials covered in detail include: 00:18: REVIVED-BCIS2:Study of Efficacy and Safety of Percutaneous Coronary Intervention (PCI) to Improve… View more

Heart Failure

Intervention
The ISCHEMIA Trial: What is the Message for the Interventionalist?
Author(s): Emmanuel Ako , Sukhjinder Nijjer , Abtehale Al-Hussaini , et al Added: 2 years ago

Prevention & Chronic Conditions

Intervention
Author(s): John Anderson , Nicola Donnelly Added: 3 years ago
A range of treatments have been developed for the management of cardiac arrhythmias. These include antiarrhythmic drugs, artificial pacemakers, implanted cardiac defibrillators and ablation of damaged or malfunctioning cardiac tissue. However, to allow a physician to choose the most suitable course of treatment for a patient, it is important that the correct diagnosis be made in an appropriate… View more

Electrophysiology & Arrhythmia
Charles Simonton
Job title: Chief Medical Officer
Personal History Dr. Charles “Chuck” Simonton is based in the San Francisco Bay Area and works at Abiomed as Chief Medical Officer, Vice President of Global Clinical and Medical Affairs. Academic History Dr. Simonton studied at Harvard Medical School between 1976 and 1980 where he earned his MD. He then went on to complete his internship, residency and chief residency in the… View more
View from the Thoraxcanter: ACC 22 Late-breaking Science Preview
Author(s): Nicolas M Van Mieghem , Joost Daemen Added: 2 years ago
In this concise episode of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their analysis of the late-breaking trials that will be presented at ACC 2022. Trials covered in detail include: 00:39: PACMAN AMI: Effects of Alirocumab on Coronary Atherosclerosis Assessed by Serial Multimodality Intracoronary Imaging in Patients… View more

Anticoagulation

Vascular Disease and Surgery